Biodesix expects to deliver $106 million to $112 million in annual revenue for 2026, representing 23% growth at the midpoint over 2025. The guidance includes consideration of recent weather events and ...

Bio-Rad Laboratories ( (BIO) ) has shared an announcement.

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

Agreement integrates Clyde Biosciences' human-relevant, CellOPTIQ cardiotoxicity screen for chemical safety assessment ...

In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...

DiVincenzo explained that QX700 is "enabling Bio-Rad to expand its served market and gain share in the entry-level digital PCR segment," and that process chromatography delivered over 20% growth in ...